One in four people will experience a stroke, with 50-70% experiencing chronic movement impairment.
While intensive rehabilitation exercise reduces movement impairment, most individuals do not receive
enough therapy during in-clinic visits to recover to their full potential and therapists routinely prescribe
home exercise programs to supplement in-clinic therapy. However, individuals struggle to adhere to these
prescribed programs. Thus, deploying strategies that promote adherence with prescribed home exercise
is critical for maximizing recovery in individuals post stroke, especially during the heightened period of
neuroplasticity early after stroke. In 2022, Medicare released 5 new reimbursement codes for Remote
Therapeutic Monitoring or RTM. These RTM codes can be billed by physical and occupational therapists
for remotely monitoring adherence to a home exercise program. These RTM codes thus represent a key
opportunity for therapists to interface with their patients at home and encourage improved adherence to
home exercises in a cost-effective way. However, there has been relatively low uptake of these new codes
due to a lack of enabling technologies that address real-world implementation barriers. Recognizing this
critical gap, we began developing MiGo Tracker, the first FDA-listed, wrist-worn exercise sensor that can
be used to seamlessly implement RTM in routine post-stroke care. MiGo Tracker monitors adherence for
any at-home exercise modality therapists already use (e.g. digital home exercise programs, printed
handouts, or videos recorded on patients’ phones; users simply don the MiGo Tracker before exercising
and remove it when they are done). Then, MiGo Tracker uploads the data via a proprietary Bluetooth-
cellular Gateway without any interaction with a user (i.e. no smartphone app or internet access is
required). Therapists can review MiGo Tracker data and document their interactions with patients on a
custom, easy-to-use RTM dashboard, which will include tools for electronic health record (EHR) integration
and billing documentation to receive reimbursement. We believe that an RTM program that uses MiGo
Tracker will readily integrate with current rehabilitation workflows, enabling useful, data-driven remote
interactions between therapists and patients that will lead to improved recovery outcomes. Our primary
objectives for this Direct to Phase II project are: Aim 1) Complete MiGo Tracker firmware development
based on end-user feedback; Aim 2) Complete online HIPAA-compliant RTM dashboard; Aim 3) Determine
the safety and effectiveness of a MiGo Tracker RTM program in a randomized controlled trial with
individuals with subacute stroke (N=50). We hypothesize that the participants in the MiGo Tracker RTM
group will have significantly higher FM Scores by a clinically meaningful amount at three-months post
stroke than the usual care group. If successful, MiGo Tracker will lead to increased home exercise
adherence and improved health outcomes for thousands of individuals following stroke.